| There were not enough data from the trial to conclude on how well Vaxzevria works for people who have already had COVID-19 | There were no additional side effects in the 345 people who received Vaxzevria in the trial and had previously had COVID-19 |
|---|---|
| Can people with allergies be vaccinated with Vaxzevria? As for all medicines, data on the use of Vaxzevria are continuously monitored | Vaxzevria must also not be given to people who have previously had capillary leak syndrome |
The decision on whether to use the vaccine in pregnant women should be made in close consultation with a healthcare professional after considering the benefits and risks.
1| Although immunocompromised people may not respond as well to the vaccine, there are no particular safety concerns | As for all vaccines, Vaxzevria should be given under close medical supervision, with the appropriate medical treatment available in case of allergic reactions |
|---|---|
| Although there are no studies on breast-feeding, no risk from breast-feeding is expected | Safety measures will be implemented for Vaxzevria in line with the to ensure that new safety information is rapidly collected and analysed |
| Allergic reactions hypersensitivity have been seen in people receiving the vaccine | |
|---|---|
| The most common side effects with Vaxzevria in the trials were usually mild or moderate and got better within a few days after vaccination | This means that there is more evidence to come about the vaccine see below , which the company is required to provide |
Other information about Vaxzevria Contents• Coleman, Justine 10 June 2020.
28